4 ASX 200 stocks rated a strong buy with an upside over 50%

Analysts are very bullish about the outlook for these ASX 200 stocks.

The S&P/ASX 200 Index (ASX: XJO) has tumbled again in early morning trade on Wednesday as inflation fears, interest rate hike concerns, and surging oil prices continue to put pressure on Australian stocks across several sectors.

During periods of market weakness, it's important to look for stocks with the strongest outlooks. Here are four ASX stocks that brokers rate as strong buys, with potential upside of over 50%.

Excited group of friends watching sports on TV and celebrating.

Image source: Getty Images

Seek Ltd (ASX: SEK)

Seek shares have tumbled another 0.6% in Wednesday morning trade, to $13.97 a piece. There is no price-sensitive news from the company this week, so the downward share price pressure is likely a mix of broad economic fears about slowing economic growth and a higher cost of living, combined with concerns about a weakening job market. Seek reported robust double-digit revenue growth for the first half of FY26, although investors were underwhelmed by the result. But it looks like analysts consider the shares well below fair value. Hiring activity is expected to slowly improve this year, and as a company so closely linked to the employment market, this is great news for Seek. Market Index data shows brokers are tipping a 58% upside to $21.94 at the time of writing.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix shares have rebounded sharply from a multi-year low in mid-February. In Wednesday morning trade, the ASX 200 biopharmaceutical stock is climbing higher again, up 0.2% to $14.77 a piece. The rebound comes off the back of a series of good-news announcements out of the company over the past couple of months. In late February, the company confirmed that it had filed a key regulatory approval in Europe. Later in March, Telix posted several announcements about its growth and development plans. Earlier this month, Telix announced that the FDA had accepted its NDA for TLX101-Px (Pixclara®) and also announced a major collaboration with US-based Regeneron Pharmaceuticals. It has also announced a 56% increase in revenue and issued FY26 guidance in the range of US$950 million to US$970 million. Brokers seem to think there is plenty more room for the stock to run too. They tip a 54% upside to $22.63 a piece, at the time of writing.

Westgold Resources Ltd (ASX: WGX)

Westgold shares are tumbling this morning, down 1.23% to $6.02 a piece, after posting a $285 million quarterly cash build ahead of the market open. The miner maintained its FY26 gold production guidance of 345,000 to 385,000 ounces despite slightly lower quarterly grades and volumes. A softening gold price has also contributed to downward pressure on many ASX gold stocks this week. But Westgold said it expects production rates to ramp up in Q4 FY26, with ventilation upgrades at Beta Hunt and Big Bell now complete and no major shutdowns planned. Its Higginsville Expansion Plan is also underway, with plans to increase processing capacity and reduce unit costs from mid FY28. Brokers tip a 55% upside to $9.31 per share over the next 12 months, at the time of writing.

Zip Co Ltd (ASX: ZIP)

Zip shares are in focus this month after rebounding from an annual low in late March. The shares have rocketed 64% higher over the past month, and the gains keep on coming. The ASX 200 stock is up another 1.24% at the time of writing to $2.44 a piece. The BNPL provider posted its Q3 FY26 results ahead of the ASX earlier this month, including a 41.5% year-on-year EBITDA increase. The company also updated FY26 guidance figures ahead of the back of the results. It looks like investor sentiment has finally turned a corner, and many are buying back into the tech company's shares. Brokers tip a 56% upside to $3.76 over the next 12 months.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

3 ASX shares given buy ratings this week offering 20% to 40% upside

Morgans expects these shares to deliver big returns.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a sour end to the trading week for investors this Friday.

Read more »

Person on a tablet with buy and sell options for a stock on the screen.
Opinions

Xero shares have crashed 64%. Here's why I'm buying

Xero shares have plunged, but I'm seeing a buying opportunity.

Read more »

Red arrow going down on a stock market chart, with share prices in red.
ASX Share Market News

ASX 200 sinks to June lows as investors brace for another RBA rate hike

The ASX 200 is heading towards the weekend on a sour note.

Read more »

Drone flying in the sky.
Share Gainers

EOS shares jump 7% as ASX 200 falls. Could $15 be next?

Could this ASX defence stock have much further to run?

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

2 ASX shares UBS says could increase 13% to 37%

These shares are primed for a rise, the broker says.

Read more »

two cute young boys dressed in business suits sit amid a pile of papers with a calculator and adding machine looking very happy for themselves.
Broker Notes

Buy, hold, sell: BOQ, Harvey Norman, Lynas shares

Here’s what brokers forecast for these three ASX shares over the next 12 months.

Read more »

Three people jumping cheerfully in clear sunny weather.
Broker Notes

5 ASX 200 shares upgraded by experts this week

Brokers have increased their ratings on AMP, Evolution, Wesfarmers, and other stocks. 

Read more »